Onconova Therapeutics Inc (ONTX) 2.34 $ONTX
Onconova Therapeutics, Inc. Highlights Rigosertib and Early-stage Programs at the 2015 American Association of Cancer Research (AACR) Annual Meeting
GlobeNewswire - Tue Apr 21, 3:01PM CDT
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the highlighting of data from its lead and other proprietary compounds at the 2015 AACR Annual Meeting being held April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia, PA.
ONTX: 2.34 (-0.05)
Onconova Therapeutics, Inc. Submits Pivotal Clinical Trial Protocol for IV Rigosertib in Higher-Risk Myelodysplastic Syndromes to FDA and EMA
GlobeNewswire - Mon Apr 20, 7:01AM CDT
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that the Company has submitted a protocol for a global pivotal study of IV rigosertib in patients with higher-risk myelodysplastic syndromes (HR-MDS) for whom prior treatment with approved hypomethylating agents has failed for regulatory review. Parallel submissions were made to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
ONTX: 2.34 (-0.05)
Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019
M2 - Mon Apr 20, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w97ksb/global_acquired) has announced the addition of the "Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019" report to their offering. The Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29% over the period 2014-2019 Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis. This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS. Entry into untapped markets is one of the major trends upcoming in the market. Currently, the market in many geographical locations remains untapped and provides immense opportunities for vendors to invest in the same. Companies that are pioneers in the development of drugs for acquired orphan blood diseases target physicians who prescribe patients these drugs instead of surgeries and chemotherapy. This has helped manufacturers to increase their product price. According to the report, patients diagnosed with acquired orphan blood diseases mostly rely on generics for the treatment. Side effects of these drugs are high and the treatment regimen requires high level of commitment from patients such as regular hospital visits and checkups. Further, the report states that most pharmaceutical and biotech companies invest extensively in the development of novel drugs to treat rare diseases. However, when marketing and distribution of drugs to potential consumers is taken into consideration, companies are hesitant to invest for the same. Low prevalence of orphan diseases makes it difficult for companies to locate the target population. Key Vendors - Alexion Pharmaceuticals - Amgen - Celgene - F. Hoffmann- La Roche - GlaxoSmithKline - Incyte Other Prominent Vendors - Cyclacel Pharmaceuticals - CTI Biopharma (Cell Therapeutics) - Eli Lilly - Gilead Sciences - Onconova Therapeutics - MebVax Therapeutics - Novartis - Sanofi - Shire Pharmaceuticals - S* Bio Pte For more information visit http://www.researchandmarkets.com/research/w9...l_acquired
CYCC: 0.96 (+0.02), GILD: 103.69 (-1.52), SHPG: 255.11 (-0.26), ALXN: 180.08 (-4.50), AMGN: 167.91 (-1.26), ONTX: 2.34 (-0.05), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22), CELGZ: 2.76 (-0.12)
Onconova Therapeutics, Inc. to Present New Data on Rigosertib and Earlier-Stage Programs at the 2015 American Association of Cancer Research (AACR) Annual Meeting
GlobeNewswire - Tue Apr 07, 8:01AM CDT
Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of pre-clinical data of its leading proprietary compounds at the 2015 AACR Annual Meeting being held April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia, PA.
ONTX: 2.34 (-0.05)
Onconova Therapeutics net loss improves in Q4 and FY14
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 7:40AM CDT
ONTX: 2.34 (-0.05)
Onconova reports 4Q loss
Automated Insights - Thu Mar 26, 3:40PM CDT
NEWTOWN, Pa. (AP) _ Onconova Therapeutics Inc. (ONTX) on Thursday reported a loss of $13.4 million in its fourth quarter.
ONTX: 2.34 (-0.05)
Onconova Therapeutics beats by $0.01
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 3:28PM CDT
ONTX: 2.34 (-0.05)
Onconova Therapeutics, Inc. Reports Recent Business Highlights and Fourth Quarter and Year-End 2014 Financial Results
GlobeNewswire - Thu Mar 26, 3:01PM CDT
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the year ended December 31, 2014.
ONTX: 2.34 (-0.05)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 11:45AM CDT
RALY: 15.53 (-0.23), GMAN: 8.49 (+0.05), VTAE: 14.05 (+0.12), YOKU: 17.03 (+0.12), NVGN: 6.54 (-0.01), ONTX: 2.34 (-0.05), ISNS: 2.80 (-0.02), EAC: 4.30 (+0.02), ONE: 2.76 (-0.01), VTL: 29.37 (+0.19), VGGL: 2.55 (-0.10), CALA: 13.41 (-0.35), ENVI: 1.77 (-0.04), CTRP: 65.57 (-0.05), VBLT: 4.23 (+0.07), PRTA: 37.35 (-0.48), NXTD: 2.53 (-0.09), OGEN: 0.92 (unch), FOLD: 12.25 (-0.05), BGI: 1.27 (-0.04)
Onconova Therapeutics, Inc. (ONTX) Rises: Stock Up 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 18, 8:32AM CDT
Onconova Therapeutics, Inc. (ONTX) was a big mover last session, as the company saw its shares rise more than 11% on the day.
LCI: 67.40 (unch), ONTX: 2.34 (-0.05)
Next Week In Biotech: Vertex PDUFA, Organon Ad Comm
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BDSI: 9.26 (+0.05), VRTX: 133.20 (-2.62), CERU: 6.27 (+0.07), FOMX: 10.46 (-0.44), ONTX: 2.34 (-0.05), PFNX: 15.80 (-0.20), OMER: 24.32 (-0.35), PGNX: 6.03 (-0.38), SYN: 2.33 (+0.01), VCYT: 9.63 (+0.40), STEM: 0.61 (-0.21), APRI: 1.61 (-0.13), KPTI: 31.49 (-1.13)
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutic Pipeline Market Review H1 2015 Available at LifeScienceIndustryResearch.com
PRWeb - Tue Mar 10, 2:01PM CDT
The report "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Radiation Toxicity. Radiation Toxicity is an acute illness caused by a dose greater than 50 rads of penetrating radiation to most or all of the body in a short time, usually a matter of minutes. Common exposures to low-dose radiation, such as X-ray or CT examinations, don't cause radiation sickness. The symptoms are Nausea and vomiting, Diarrhea, Headache, Fever, Dizziness and disorientation, Weakness, fatigue, Hair loss, bloody vomit and stools, infections, poor wound healing, low blood pressure. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.lifescienceindustryresearch.com/ra...-2015.html .
PSTI: 2.82 (-0.05), ONTX: 2.34 (-0.05), CBLI: 3.40 (+0.10)
Heavy Institutional Buying Is Occurring In MEI Pharma, Topline Data Due In Mid-March
StockMatusow - Seeking Alpha - Thu Feb 26, 7:30AM CST
Written by Scott Matusow and Michael Kovar MEI Pharma (NASDAQ: MEIP ) specializes in oncology and is currently focused on the clinical development of its lead drug candidate Pracinostat. Pracinostat is an orally available histone deacetylase...
ONTX: 2.34 (-0.05), MEIP: 2.16 (-0.02), CELG: 118.71 (+2.62)
Onconova Therapeutics (ONTX) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 7:34AM CST
Onconova Therapeutics (ONTX) Enters Oversold Territory
ONTX: 2.34 (-0.05)
Nasdaq stocks posting largest volume increases
AP - Tue Feb 03, 5:44PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
HIHO: 3.34 (-0.01), GTWN: 18.10 (unch), ONTX: 2.34 (-0.05), JAXB: 11.38 (+0.05), KTWO: 22.87 (-0.71), MTSL: 1.81 (+0.08), HTWO: 9.70 (-0.11), OBAS: 7.20 (unch), GPIC: 12.00 (-0.70), SSYS: 51.28 (-3.29), WAYN: 13.63 (+0.35), ADVS: 43.54 (-0.34)
Onconova plummets as Baxter bails on development of rigosertib
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 9:51AM CST
ONTX: 2.34 (-0.05)
Onconova Announces Clinical Development Plan for Rigosertib in Higher Risk Myelodysplastic Syndrome (HR-MDS) Patients After Failure of Treatment With Hypomethylating Agents (HMAs)
GlobeNewswire - Mon Feb 02, 3:01PM CST
-- Clarity of the design of Phase 3 global replication trial of IV rigosertib in HR-MDS
ONTX: 2.34 (-0.05)
Onconova Therapeutics, Inc. to Present at Upcoming Investor Conferences in February
GlobeNewswire - Fri Jan 30, 9:40AM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced its participation in two investor conferences in February:
ONTX: 2.34 (-0.05)
Onconova Therapeutics Appoints Dr. Steven M. Fruchtman as Chief Medical Officer
GlobeNewswire - Mon Jan 12, 4:02PM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the appointment of Steven M. Fruchtman, M.D., as Chief Medical Officer and Senior Vice President, Research and Development. Dr. Fruchtman is a board certified hematologist with extensive industry experience in clinical research for myelodysplastic syndromes (MDS), hematologic malignancies and solid tumors. He will report to Thomas J. McKearn, M.D., Ph.D., the Company's President, Research and Development, and will provide worldwide strategic planning and leadership for the clinical development and registration of rigosertib and other pipeline product candidates.
ONTX: 2.34 (-0.05)
Onconova Therapeutics, Inc. Highlights Rigosertib and Early-stage Programs at the 2015 American Association of Cancer Research (AACR) Annual Meeting
GlobeNewswire - Tue Apr 21, 3:01PM CDT
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the highlighting of data from its lead and other proprietary compounds at the 2015 AACR Annual Meeting being held April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia, PA.
ONTX: 2.34 (-0.05)
Onconova Therapeutics, Inc. Submits Pivotal Clinical Trial Protocol for IV Rigosertib in Higher-Risk Myelodysplastic Syndromes to FDA and EMA
GlobeNewswire - Mon Apr 20, 7:01AM CDT
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that the Company has submitted a protocol for a global pivotal study of IV rigosertib in patients with higher-risk myelodysplastic syndromes (HR-MDS) for whom prior treatment with approved hypomethylating agents has failed for regulatory review. Parallel submissions were made to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
ONTX: 2.34 (-0.05)
Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019
M2 - Mon Apr 20, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w97ksb/global_acquired) has announced the addition of the "Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019" report to their offering. The Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29% over the period 2014-2019 Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis. This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS. Entry into untapped markets is one of the major trends upcoming in the market. Currently, the market in many geographical locations remains untapped and provides immense opportunities for vendors to invest in the same. Companies that are pioneers in the development of drugs for acquired orphan blood diseases target physicians who prescribe patients these drugs instead of surgeries and chemotherapy. This has helped manufacturers to increase their product price. According to the report, patients diagnosed with acquired orphan blood diseases mostly rely on generics for the treatment. Side effects of these drugs are high and the treatment regimen requires high level of commitment from patients such as regular hospital visits and checkups. Further, the report states that most pharmaceutical and biotech companies invest extensively in the development of novel drugs to treat rare diseases. However, when marketing and distribution of drugs to potential consumers is taken into consideration, companies are hesitant to invest for the same. Low prevalence of orphan diseases makes it difficult for companies to locate the target population. Key Vendors - Alexion Pharmaceuticals - Amgen - Celgene - F. Hoffmann- La Roche - GlaxoSmithKline - Incyte Other Prominent Vendors - Cyclacel Pharmaceuticals - CTI Biopharma (Cell Therapeutics) - Eli Lilly - Gilead Sciences - Onconova Therapeutics - MebVax Therapeutics - Novartis - Sanofi - Shire Pharmaceuticals - S* Bio Pte For more information visit http://www.researchandmarkets.com/research/w9...l_acquired
CYCC: 0.96 (+0.02), GILD: 103.69 (-1.52), SHPG: 255.11 (-0.26), ALXN: 180.08 (-4.50), AMGN: 167.91 (-1.26), ONTX: 2.34 (-0.05), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22), CELGZ: 2.76 (-0.12)
Onconova Therapeutics, Inc. to Present New Data on Rigosertib and Earlier-Stage Programs at the 2015 American Association of Cancer Research (AACR) Annual Meeting
GlobeNewswire - Tue Apr 07, 8:01AM CDT
Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of pre-clinical data of its leading proprietary compounds at the 2015 AACR Annual Meeting being held April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia, PA.
ONTX: 2.34 (-0.05)
Onconova Therapeutics net loss improves in Q4 and FY14
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 7:40AM CDT
ONTX: 2.34 (-0.05)
Onconova reports 4Q loss
Automated Insights - Thu Mar 26, 3:40PM CDT
NEWTOWN, Pa. (AP) _ Onconova Therapeutics Inc. (ONTX) on Thursday reported a loss of $13.4 million in its fourth quarter.
ONTX: 2.34 (-0.05)
Onconova Therapeutics beats by $0.01
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 3:28PM CDT
ONTX: 2.34 (-0.05)
Onconova Therapeutics, Inc. Reports Recent Business Highlights and Fourth Quarter and Year-End 2014 Financial Results
GlobeNewswire - Thu Mar 26, 3:01PM CDT
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the year ended December 31, 2014.
ONTX: 2.34 (-0.05)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 11:45AM CDT
RALY: 15.53 (-0.23), GMAN: 8.49 (+0.05), VTAE: 14.05 (+0.12), YOKU: 17.03 (+0.12), NVGN: 6.54 (-0.01), ONTX: 2.34 (-0.05), ISNS: 2.80 (-0.02), EAC: 4.30 (+0.02), ONE: 2.76 (-0.01), VTL: 29.37 (+0.19), VGGL: 2.55 (-0.10), CALA: 13.41 (-0.35), ENVI: 1.77 (-0.04), CTRP: 65.57 (-0.05), VBLT: 4.23 (+0.07), PRTA: 37.35 (-0.48), NXTD: 2.53 (-0.09), OGEN: 0.92 (unch), FOLD: 12.25 (-0.05), BGI: 1.27 (-0.04)
Onconova Therapeutics, Inc. (ONTX) Rises: Stock Up 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 18, 8:32AM CDT
Onconova Therapeutics, Inc. (ONTX) was a big mover last session, as the company saw its shares rise more than 11% on the day.
LCI: 67.40 (unch), ONTX: 2.34 (-0.05)
Next Week In Biotech: Vertex PDUFA, Organon Ad Comm
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BDSI: 9.26 (+0.05), VRTX: 133.20 (-2.62), CERU: 6.27 (+0.07), FOMX: 10.46 (-0.44), ONTX: 2.34 (-0.05), PFNX: 15.80 (-0.20), OMER: 24.32 (-0.35), PGNX: 6.03 (-0.38), SYN: 2.33 (+0.01), VCYT: 9.63 (+0.40), STEM: 0.61 (-0.21), APRI: 1.61 (-0.13), KPTI: 31.49 (-1.13)
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutic Pipeline Market Review H1 2015 Available at LifeScienceIndustryResearch.com
PRWeb - Tue Mar 10, 2:01PM CDT
The report "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Radiation Toxicity. Radiation Toxicity is an acute illness caused by a dose greater than 50 rads of penetrating radiation to most or all of the body in a short time, usually a matter of minutes. Common exposures to low-dose radiation, such as X-ray or CT examinations, don't cause radiation sickness. The symptoms are Nausea and vomiting, Diarrhea, Headache, Fever, Dizziness and disorientation, Weakness, fatigue, Hair loss, bloody vomit and stools, infections, poor wound healing, low blood pressure. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.lifescienceindustryresearch.com/ra...-2015.html .
PSTI: 2.82 (-0.05), ONTX: 2.34 (-0.05), CBLI: 3.40 (+0.10)
Heavy Institutional Buying Is Occurring In MEI Pharma, Topline Data Due In Mid-March
StockMatusow - Seeking Alpha - Thu Feb 26, 7:30AM CST
Written by Scott Matusow and Michael Kovar MEI Pharma (NASDAQ: MEIP ) specializes in oncology and is currently focused on the clinical development of its lead drug candidate Pracinostat. Pracinostat is an orally available histone deacetylase...
ONTX: 2.34 (-0.05), MEIP: 2.16 (-0.02), CELG: 118.71 (+2.62)
Onconova Therapeutics (ONTX) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 7:34AM CST
Onconova Therapeutics (ONTX) Enters Oversold Territory
ONTX: 2.34 (-0.05)
Nasdaq stocks posting largest volume increases
AP - Tue Feb 03, 5:44PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
HIHO: 3.34 (-0.01), GTWN: 18.10 (unch), ONTX: 2.34 (-0.05), JAXB: 11.38 (+0.05), KTWO: 22.87 (-0.71), MTSL: 1.81 (+0.08), HTWO: 9.70 (-0.11), OBAS: 7.20 (unch), GPIC: 12.00 (-0.70), SSYS: 51.28 (-3.29), WAYN: 13.63 (+0.35), ADVS: 43.54 (-0.34)
Onconova plummets as Baxter bails on development of rigosertib
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 9:51AM CST
ONTX: 2.34 (-0.05)
Onconova Announces Clinical Development Plan for Rigosertib in Higher Risk Myelodysplastic Syndrome (HR-MDS) Patients After Failure of Treatment With Hypomethylating Agents (HMAs)
GlobeNewswire - Mon Feb 02, 3:01PM CST
-- Clarity of the design of Phase 3 global replication trial of IV rigosertib in HR-MDS
ONTX: 2.34 (-0.05)
Onconova Therapeutics, Inc. to Present at Upcoming Investor Conferences in February
GlobeNewswire - Fri Jan 30, 9:40AM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced its participation in two investor conferences in February:
ONTX: 2.34 (-0.05)
Onconova Therapeutics Appoints Dr. Steven M. Fruchtman as Chief Medical Officer
GlobeNewswire - Mon Jan 12, 4:02PM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the appointment of Steven M. Fruchtman, M.D., as Chief Medical Officer and Senior Vice President, Research and Development. Dr. Fruchtman is a board certified hematologist with extensive industry experience in clinical research for myelodysplastic syndromes (MDS), hematologic malignancies and solid tumors. He will report to Thomas J. McKearn, M.D., Ph.D., the Company's President, Research and Development, and will provide worldwide strategic planning and leadership for the clinical development and registration of rigosertib and other pipeline product candidates.
ONTX: 2.34 (-0.05)
